Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 9/20 | 0.37 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025241 | 1.00 | HTR2A (0.37) | HTR2AHTR2CKCNH2AKR1C3ELOVL6 | |
| SCHEMBL2025920 | 0.88 | CCR6 (0.37) | HTR2AHTR2CKCNH2ELOVL6DRD2 | |
| SCHEMBL2025917 | 0.88 | CCR6 (0.37) | HTR2AHTR2CKCNH2ELOVL6DRD2 | |
| SCHEMBL4257389 | 0.85 | AKR1C3 (0.39) | HTR2AHTR2CKCNH2AKR1C3PTGS2 | |
| SCHEMBL4257392 | 0.85 | AKR1C3 (0.39) | HTR2AHTR2CKCNH2AKR1C3PTGS2 | |
| SCHEMBL2022436 | 0.84 | AKR1C3 (0.55) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2022434 | 0.84 | AKR1C3 (0.55) | AKR1C3PTGS2AKR1C2AKR1C1 | |
| SCHEMBL2652180 | 0.83 | GCK (0.47) | HTR2AHTR2CKCNH2AKR1C3PTGS2 | |
| SCHEMBL2652182 | 0.83 | GCK (0.47) | HTR2AHTR2CKCNH2AKR1C3PTGS2 | |
| SCHEMBL2018407 | 0.82 | HTT (0.35) | HTR2AHTR2CKCNH2GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | HTR2A 1329/4885HTR2C 1253/4885KCNH2 1011/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | HTR2A 1329/4885HTR2C 1253/4885KCNH2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.